Does Medicaid Cover GLP-1s in 2026? Coverage by Situation

Last updated: August 2026 · Written by Ash Heleka

Medicaid covers GLP-1 medications like Ozempic and Mounjaro for type 2 diabetes in all 50 states. For weight loss alone, only about 11 state Medicaid programs cover drugs like Wegovy and Zepbound as of August 2026, down from 16 in October 2025. The answer depends less on which state you live in and more on why the drug is being prescribed, which is what this guide breaks down.

Most articles on this topic give you a state list that goes stale within months. Four states dropped weight loss coverage between October 2025 and January 2026, then Utah and Massachusetts followed in mid-2026. So instead of a state table, I am going to walk through coverage by situation, because your diagnosis matters more than your zip code. Two of these situations get you covered in every state, and almost nobody writing about this mentions them.

Does Medicaid Cover Ozempic and Mounjaro for Type 2 Diabetes?

Yes, in every state. Federal Medicaid rules require states to cover outpatient drugs from manufacturers in the Medicaid rebate program for their FDA-approved uses, and diabetes is not on the list of categories states are allowed to exclude. So Ozempic, Mounjaro, Rybelsus, and Trulicity are covered by every state Medicaid program when prescribed for type 2 diabetes.

Covered does not mean automatic. Most states put GLP-1s behind prior authorization, and many require step therapy, meaning you try metformin or another cheaper drug first. Some states also require a recent A1C reading. Your prescriber handles the paperwork, but expect the approval to take days to a few weeks. If you want to understand how diabetes and weight loss prescribing differ, I cover that in GLP-1 for type 2 diabetes vs weight loss.

Does Medicaid Cover Wegovy or Zepbound for Weight Loss?

Only in a minority of states, and the list is shrinking fast. Federal law treats weight loss drugs as an optional category that states can exclude, and most do. According to KFF’s January 2026 analysis, 13 state Medicaid programs covered GLP-1s for obesity treatment as of January 2026, down from 16 in October 2025 after California, New Hampshire, Pennsylvania, and South Carolina cut coverage.

It kept shrinking through 2026. Utah’s pilot program ended June 30, and Massachusetts stopped covering anti-obesity GLP-1s on July 1, a change MassHealth said affects at least 22,000 residents and saves the state roughly $15 million a year. That leaves around 11 states covering GLP-1s for obesity alone as of August 2026.

The reason is money. KFF reports that gross Medicaid spending on GLP-1s grew from about $1 billion in 2019 to nearly $9 billion in 2024, with prescriptions up sevenfold. States facing budget pressure cut the optional category first, and weight loss coverage is the optional category.

If your state does cover weight loss GLP-1s, expect strict conditions. Typical requirements include a BMI threshold, documented participation in a lifestyle program, and reauthorization every few months with proof you are losing weight.

Which Situations Get GLP-1 Coverage in Every State?

Three diagnoses require Medicaid coverage no matter where you live, because they are FDA-approved indications outside the weight loss exclusion. This is the part most coverage articles miss, and it changes the answer for a lot of people.

The heart disease and sleep apnea rows are the ones worth staring at. If you have established cardiovascular disease and a BMI of 27 or higher, Wegovy is FDA-approved to reduce your risk of heart attack and stroke, and that indication is not weight loss, so states must cover it. Same logic for Zepbound if you have moderate to severe obstructive sleep apnea and obesity. North Carolina Medicaid, for example, published updated criteria in late 2025 specifically covering Wegovy and Zepbound for these non-weight-loss indications.

This is not a loophole you can talk your way into. You need the actual diagnosis documented, and prior authorization still applies. But if you have untreated sleep apnea and have been assuming Medicaid would never pay for a GLP-1, a sleep study might change your situation entirely. Bring it up with your doctor. I wrote a separate guide on how to talk to your doctor about GLP-1 medications if you want a script.

What Is the BALANCE Model and Will It Expand Coverage?

BALANCE is a voluntary CMS pilot, announced in December 2025, that lets state Medicaid programs cover GLP-1s for obesity at confidential negotiated prices starting May 2026. Per CMS and KFF’s May 2026 breakdown, states can join on a rolling basis through January 1, 2027, and the model covers Wegovy, Ozempic, Rybelsus, Mounjaro, the oral pill Foundayo, and the KwikPen formulation of Zepbound.

Two caveats matter. First, participation is voluntary on all sides. Your state has to opt in, and it can drop out later. Second, the Medicare half of the model has been delayed indefinitely, so the momentum is not guaranteed. My read is that BALANCE gives budget-strapped states a cheaper path back to coverage, but I would not build a treatment plan around a state joining. Watch your state Medicaid agency’s announcements rather than national headlines. Medicare has its own separate rules, which I cover in the Medicare GLP-1 coverage guide.

How Much Will You Pay If Medicaid Covers Your GLP-1?

Almost nothing. Medicaid cost sharing is capped at nominal amounts under federal rules, so a covered GLP-1 prescription typically costs $0 to $8 depending on your state and income level. That makes Medicaid coverage, when you can get it, the cheapest possible way to be on these medications. It also makes losing coverage brutal, because the jump from a few dollars to cash-pay prices is the largest cliff in the entire GLP-1 market.

One thing that surprises people is that manufacturer savings cards cannot soften that cliff. The Lilly and Novo Nordisk copay cards that get commercially insured patients to $25 a month explicitly exclude anyone enrolled in Medicaid, Medicare, or other government insurance. That exclusion applies even if Medicaid is denying the specific drug. More on those programs in the copay cards and patient assistance guide.

What If Your State Does Not Cover GLP-1s for Weight Loss?

You have three realistic paths, and I have watched people work through all of them since I started tracking this market while on Mounjaro myself.

Path 1, check the required-coverage indications first. Before paying cash, rule out the diagnoses in the table above. A sleep study or cardiology workup costs Medicaid far less than a year of GLP-1 therapy, and either one can convert you from “excluded” to “covered in every state.”

Path 2, appeal a denial if you are in a covering state. If your state covers weight loss GLP-1s and you were denied on prior authorization, appeal. Denials often turn on missing documentation rather than eligibility. I built a template for this in the insurance appeal letter guide.

Path 3, cash pay. If Medicaid genuinely will not cover it, compounded GLP-1s are the affordable fallback. Verified August 2026, compounded semaglutide runs $129 to $199 per month from licensed telehealth providers, LillyDirect sells brand-name Zepbound vials for $299 to $449 per month, and NovoCare offers Wegovy starter doses at $199 per month. None of these require insurance. The full price rundown is in my cheapest GLP-1 online guide.

The Bottom Line

Whether Medicaid covers your GLP-1 comes down to the diagnosis on the prescription. Type 2 diabetes, cardiovascular disease with Wegovy, and obstructive sleep apnea with Zepbound get required coverage in every state. Obesity alone gets coverage in only about 11 states as of August 2026, and that number has fallen twice this year. If you are in the excluded majority, work the diagnosis angle first, then the BALANCE model if your state joins, and treat $129 to $199 per month compounded semaglutide as the cash-pay floor. Start with our provider comparison to see current verified prices side by side.

Frequently Asked Questions

Does Medicaid cover Ozempic for weight loss?

No. Ozempic is FDA-approved for type 2 diabetes, not weight loss, so Medicaid covers it only with a diabetes diagnosis. Prescribing it off-label for weight loss will almost always be denied. Wegovy is the semaglutide product approved for weight management, and its coverage depends on your state.

Which states cover Wegovy or Zepbound for weight loss under Medicaid?

About 11 state Medicaid programs cover GLP-1s for obesity treatment as of August 2026, down from 16 in October 2025. Because states keep dropping coverage, check your state Medicaid agency’s preferred drug list directly rather than relying on a published state list, which goes stale quickly.

Does Medicaid cover Zepbound for sleep apnea?

Yes, in every state. The FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity in December 2024, and that indication falls under required Medicaid drug coverage rather than the optional weight loss category. You need a documented OSA diagnosis, usually from a sleep study, and prior authorization still applies.

Can I use a Wegovy or Zepbound savings card if I have Medicaid?

No. Both the Novo Nordisk and Eli Lilly savings card programs exclude anyone enrolled in Medicaid, Medicare, or other government insurance, even if your plan denies the drug. Cash-pay programs like LillyDirect ($299 to $449 per month for Zepbound vials) and NovoCare ($199 per month for Wegovy starter doses) are open to Medicaid enrollees paying out of pocket.

What is the BALANCE model?

BALANCE is a voluntary CMS pilot announced in December 2025 that lets state Medicaid programs cover GLP-1s for obesity at negotiated prices, with state participation starting May 2026. States opt in on a rolling basis through January 2027 and can later withdraw. The Medicare portion of the model has been delayed indefinitely.

This article is for informational purposes only and does not constitute medical advice. Coverage rules and pricing are based on publicly available data as of August 2026 and may change. Always verify coverage with your state Medicaid agency and consult a qualified healthcare provider before starting any medication. ClearMetabolic may earn a commission through provider links on this page. See our full disclosure.

Related

Guides:

• Medicare Coverage · Insurance Coverage · Without Insurance
• Copay Cards and Patient Assistance · Insurance Appeal Letter Template · Cash Pay vs Insurance
• Cheapest GLP-1 Online · Does TRICARE Cover GLP-1s? · T2D vs Weight Loss Dosing

Medications: Ozempic · Wegovy · Mounjaro · Zepbound

Compare: All Providers · All Guides